PyrAmes - Blood pressure is where all treatment decisions begin.

About PyrAmes & Our Technology

Our Platforms

Introducing Boppli^™

Accurate, non-invasive, continuous, wireless BP monitoring for the NICU and pediatric patients.

Learn More

Introducing Bosimi^™

Adult inpatient & emergency care cNIBP.

Learn More

Introducing Bosimi At-Home^™

Diagnostics, treatment validation & home medical management.

Learn More

cNIBP Health Impact

PyrAmes provides an option to continuously monitor blood pressure cNIBP for patients of all ages.

Over 50% of NICU Admissions

could benefit from BP monitoring but would not receive an arterial line because it is invasive and costly.¹

50% of Adults have High BP

50% of adults are affected by high blood pressure in the US, increasing their mortality rates.²

7.6 Million Deaths Annually

Raised blood pressure (BP) is responsible for 7.6 million deaths worldwide annually.³

cNIBP & Early Detection

cNIBP has the potential for early detection of conditions within preterm infants and adults.

1. Haidari, E. S., Lee, H. C., Illuzzi, J. L., Phibbs, C. S., Lin, H., & Xu, X. (2020). Hospital variation in admissions to neonatal intensive care units by diagnosis severity and category. Journal of Perinatology, doi:10.1038/s41372-020-00775-z

2. https://www.cdc.gov/bloodpressure/facts.htm

3. https://pubmed.ncbi.nlm.nih.gov/22157565/

News & Updates

April 20, 2021

PyrAmes Raises $6 Million in Series A Financing

Cupertino, CA, -- (Marketwired - April 20, 2021) – PyrAmes, Inc., a digital healthcare company focused on innovative products for continuous blood pressure monitoring, today announced the completion of a $6 million Series A financing. The investment round was led by GSR Ventures, with co-investments from Keytone Ventures, XTX Ventures and other investors. (more…)

May 18, 2020

FDA Breakthrough Device Designation

PyrAmes Inc. is proud to announce that the FDA has granted Breakthrough Device Designation (BDD) to Boppli™, which fills the unmet need of monitoring the blood pressure of critically ill infants when an invasive arterial catheter cannot be used due to the risk of complications and adverse effects. (more…)

April 15, 2020

SWPDC Pediatric Device Award

PyrAmes is honored to be selected by the Southwest National Pediatric Device Innovation Consortium (SWPDC) as a winner of the SWPDC Spring Competition. The SouthWest National Pediatric Device Innovation Consortium (SWPDC) is a “free no-strings-attached” virtual accelerator based at Texas Children’s Hospital and Baylor College of Medicine that supports pediatric device innovators nationwide throughout the pediatric device life cycle. The goal of the SWPDC is to accelerate commercialization and clinical use of novel pediatric devices.

View All News